



Hemogenyx Pharma Plc - Result of AGM

6/27/2018

RNS Number : 7699S

Hemogenyx Pharmaceuticals PLC

27 June 2018

Hemogenyx Pharmaceuticals Plc
("Hemogenyx" or the "Company")

Result of AGM

Hemogenyx Pharmaceuticals Plc (LSE: HEMO), the biotechnology company developing novel therapies to transform bone marrow, or blood stem cell, transplantation for the treatment of blood diseases, announces that all resolutions proposed at the Annual General Meeting held earlier today were duly passed.

Enquiries:



Hemogenyx Pharmaceuticals Limited
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder

www.hemogenyx.com
Via Walbrook PR

Sir Marc Feldmann, Executive Chairman

Optiva Securities Ltd
Christian Dennis

Tel: +44 (0)20 3137 1902

Shard Capital Partners LLP
Damon Heath, Erik Woolgar

Tel: +44 (0)20 7186 9950

Peterhouse Corporate Finance Limited
Lucy Williams, Duncan Vasey

Tel: +44 (0)20 7469 0930

Walbrook PR (UK Media & Investor Relations)
Paul McManus

Tel: +44 (0)20 7933 8780 or **hemogenyx@walbrookpr.com**
Mob: +44 (0)7980 541 893

US Media enquiries
Lowell Goodman

Tel: +1 (323) 646-3249 or **Lowell@corbomitecomms.com**

About Hemogenyx Pharmaceuticals Plc

Hemogenyx Pharmaceuticals Plc is a publicly traded company (LSE: HEMO) headquartered in London, with its wholly owned U.S. operating subsidiary, HemoGenyx LLC, located in its state-of-the-art research facility in Brooklyn, New York. HemoGenyx is a preclinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies and treatments for blood diseases such as leukemia and lymphoma. The company's leading technologies aim to change the way in which bone marrow/hematopoietic stem cell (BM/HSC) transplants are performed and improve their efficacy. HemoGenyx's two distinct and complementary products include an immunotherapy product for patient conditioning-the CDX bi-specific antibody-and a cell therapy product for BM/HSC transplantation-the HuPHEC. Each of these products holds the potential to revolutionize the way BM/HSC transplants are being performed, offering solutions that mitigate the dangers and limitations associated with the current standard of care. For more information, visit www.hemogenyx.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

RAGSEAFSWFAEDM